FB102 Phase 1b results lift Forte Biosciences and FBRX
Forte Biosciences reported positive Phase 1b results for FB102 in facial vitiligo, showing a 21.7% placebo-adjusted FVASI improvement at week 24 and an early signal by day 64. More severe baseline disease yielded greater benefits, with 84% of treated patients improving by week 24 and a favorable safety profile. The data boosted FBRX shares, signaling potential for pivotal trials and nearer-term upside.
View signal analysis